research use only

Necrostatin 2 racemate (Nec-1s) RIPK1 Inhibitor

Name: Necrostatin 2 racemate (Nec-1s)
Brand: Selleck Chemicals
SKU: S8641
Availability: InStock
Rating: 5 (70 reviews)

Cat.No.S8641

Necrostatin 2 racemate (Nec-1s, 7-Cl-O-Nec1, Necrostatin-1 stable, Necrostatin 1S) is a stable variant of Necrostatin-1. This compound is a more specific RIPK1 inhibitor lacking the IDO-targeting effect, with >1000-fold more selective for RIPK1 than for any other kinase out of 485 human kinases.

Chemical Structure

Molecular Weight: 277.71

Jump to

Quality Control

Batch: Purity: 99.83%

99.83

Products Often Used Together with Necrostatin 2 racemate (Nec-1s)

Ferrostatin-1 (Fer-1)

It and Ferrostatin-1 inhibit the BAY-induced reduction in cell viability to a similar extent in melanoma cells.

Z-VAD-FMK

It and Z-VAD-FMK partially reduce cell death in response to heme plus Pam3 in WT bone marrow-derived macrophages.

GSK872

It and GSK'872 as inhibitors of apoptosis do not induce cell death in trans-differentiated 3T3-L1 cells.

Lipopolysaccharides

It abolishes the increase in TNFalpha synthesis by LPS with zVAD in RIPK1 D138N cells.

Necrostatin-1 (Nec-1)

It and Necrostatin-1 exert neuroprotective and anti-inflammatory effects in MPTP-induced PD mice.

Related Targets	Bcl-2 Caspase K-Ras PD-1/PD-L1 Ferroptosis p53 Apoptosis related Synthetic Lethality STAT TNF-alpha
Other RIP kinase Products	Necrostatin-1 (Nec-1) GSK872 Mito-TEMPO RIPA-56 GSK2982772 GSK'963 GSK583 GSK2983559 (compound 3) Resibufogenin GSK'547

Cell Culture, Treatment & Working Concentration

Cell Lines	Assay Type	Concentration	Incubation Time	Activity Description	PMID
U118 cells	Function assay	200 μM		Nec-1s reduces PI incorporation in edelfosine-treated U118 cells.	25593994
MEFs	Function assay	20 µM	10 min	The cylindromatosis cleavage induced by TNFα could be inhibited by Nec-1s.	28701375
Jurkat	Function assay		30 hrs	Inhibition of death receptor signaling mediated necroptotic cell death in human Jurkat cell deficient in FADD assessed as cell viability after 30 hrs by ATP based viability assay in presence of TNFalpha, IC50 = 0.206 μM.	16408008
Jurkat	Function assay			Effective concentration required for inhibition of necroptosis in FADD deficient Jurkat T cells treated with TNF-alpha, EC50 = 0.21 μM.	16153840
Click to View More Cell Line Experimental Data

Solubility

In vitro
Batch:

DMSO : 56 mg/mL (201.64 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 56 mg/mL

Water : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	2.800mg/ml (10.08mM)	Taking the 1 mL working solution as an example, add 50 μL of clarified DMSO stock solution of 56 mg/ml to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify it; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	2.800mg/ml (10.08mM)	Taking the 1 mL working solution as an example, add 50 μL of 56 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

% Tween 80

% ddH₂O

% DMSO

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	277.71	Formula	C₁₃H₁₂ClN₃O₂	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	852391-15-2	--		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	7-Cl-O-Nec1, Necrostatin-1 stable, Necrostatin 1S			Smiles	CN1C(=O)C(NC1=O)CC2=CNC3=C2C=CC=C3Cl

Mechanism of Action

Targets/IC₅₀/Ki	RIPK1
In vitro	Necrostatin 2 racemate (Nec-1s) is a potent inhibitor of RIPK1 and cellular necroptosis while lacking IDO inhibitory activity.
In vivo	Necrostatin 2 racemate (Nec-1s) is effective in reducing brain injuries. It is a superior inhibitor suitable for use in vivo lacking a paradoxical sensitizing effect in TNF-induced lethality. This compound possesses several advantageous pharmacokinetic and pharmacodynamic characteristics in comparison to Nec-1. Its safety profile is also superior to that of Nec-1 for reduced in vivo and in vitro toxicity.
References	[1] https://pubmed.ncbi.nlm.nih.gov/23190609/ [2] https://pubmed.ncbi.nlm.nih.gov/30081531/ [3] https://pubmed.ncbi.nlm.nih.gov/36198273/

Applications

Methods	Biomarkers	Images	PMID
Growth inhibition assay	Cell viability		29527209

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):